DXP-593

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameDXP-593
Drug Alias NameBGB DXP593DXP-593
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexicoSouth Africa +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinglomics Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinglomics Biopharmaceuticals Co Ltd
Inactive CompaniesBeOne Medicines Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A